Alnylam Pharmaceuticals, Inc.
COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF MUTANT EGFR GENE
Last updated:
Abstract:
The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a mutant Epidermal Growth Factor Receptor (EGFR), and methods of using the dsRNA to inhibit expression of mutant EGFR.
Status:
Application
Type:
Utility
Filling date:
3 Mar 2020
Issue date:
3 Dec 2020